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life, with an increase in costs of about €540–640 and €680–
780/patient/year with solifenacin and tolterodine, respectively.
Cost-utility analysis indicates that solifenacin dominates toltero-
dine and has an ICUR in the range €7,600—18,600/QALY com-
pared to no treatment. In the subgroup of patients incontinent
at baseline and who respond to the therapy, the increase in costs
with solifenacin results in €100–400/patient/year. The expected
incremental expenditure of the theoretical reimbursement deci-
sion is about €23 millions/year, with an ICUR of about €600–
2,400/QALY. CONCLUSIONS: Solifenacin has the potential to
improve current clinical outcomes of many Italian OAB
patients, at a mean net cost of €540–640/year. The ICUR of the
hypothesized reimbursement decision can expected to be very
favourable.
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OBJECTIVES: Recent clinical data show that a supplemented
very low protein diet (sVLPD) allows to postpone dialysis (HD/
PD) of about one year without increasing risk of death or hospi-
talization in CKD5 elderly patients; here we compared beneﬁts
and costs of sVLPD vs dialysis in these patients. METHODS: A
cost-beneﬁt analysis technique was applied. Direct medical and
non-medical beneﬁts and costs were analysed, from the perspec-
tive of the Italian National Health Service (NHS). We quantiﬁed
resource adsorption for dialysis, keto-amino acid supplements,
hospitalizations, pharmacological therapy, blood and instrumen-
tal tests, medical visits, reimbursement for transportation of
patients in HD and for home treatment of patients in PD. Prices
and tariffs applied in 2007 were used. Results are expressed as
mean € per patient-year. RESULTS: Data from a subgroup of
patients with GFR of 5–7 ml/min/1.73 m2 BSA, participating in a
RCT were analysed. Thirty patients were randomized to dialysis
(age = 77.2 4.6 years; 23 HD, 7 PD); 27 to sVLPD (age = 78.6 6.5
years): during the follow up 19 switched to HD and 2 to PD.
Follow-up was, in mean, 3.24 years in dialysis, and 3.27 years in
sVLPD group, including both diet and following period on dialy-
sis. Erythropoietin (EPO) dose was on average 7,160 IU/patient-
week in sVLPD patients, and 8,104 IU/patient-week in dialysis
patients. Patients cost €45,209/patient-year on dialysis; €10,786/
patient-year during sVLPD and €40,900/patient-year when
shifted to dialysis. Dialysis was the cost driver (€26,000/patient-
year, 60% of costs), main beneﬁt to NHS derived from saving
this costs in the ﬁrst year (mean period in sVLPD) of treatment.
CONCLUSIONS: to our knowledge this is the ﬁrst study analys-
ing beneﬁts and costs of initiating sVLPD whereas dialysis in
CKD5 patients. sVLPD allows to save 1 year per patient of dialysis
and to gain €34,000/patient-year on the NHS’s perspective.
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OBJECTIVES: Overactive bladder is a dysfunction of the lower
urinary tract which causes signiﬁcant impairment to patients’
quality of life and affects a relatively large portion of the popu-
lation. Patients who have failed all conservative treatment
options are faced with managing their incontinence symptoms
through the daily use of incontinence pads, or their retention by
frequent clean intermittent self catheterization. Patients with
severe symptoms may be offered a highly invasive surgical pro-
cedure, such as myectomy, urinary diversion or bladder augmen-
tation but these are all associated with serious complications and
morbidity. The objective is to assess cost-effectiveness of sacral
neuromodulation as a second line treatment option for patients
with OAB in the Dutch setting. METHODS: An economic model
comparing sacral neuromodulation with optimal medical treat-
ment was developed. Health states were deﬁned in terms of ‘cure’
deﬁned as no incontinence or a clinical improvement > 90%,
or ‘improvement’ deﬁned as 50% or greater reduction in main
continence or urgency frequency symptoms. Associated clinical
effectiveness and utility values were taken from published inter-
national clinical studies, and treatment costs were based on
national sources. Analyses from the health care payer’s perspec-
tive were performed for a 10 year time-horizon. RESULTS: The
results of the deterministic cost-effectiveness analysis showed
that sacral neuromodulation provides an additional 1.53 QALY’s
against extra cost of €8222 per patient over a 10 year period.
The corresponding cost-effectiveness ratio was €5732 per QALY
gained. Probabilistic sensitivity analysis showed the robustness of
these results. CONCLUSIONS: Use of sacral neuromodulation
as a treatment option for patients with OAB in The Netherlands
will improve patients’ outcomes at a reasonable cost.
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OBJECTIVES: Performing a 10-year horizon (2007/2016) cost-
effectiveness analysis of the integrated Spanish Renal Replace-
ment Therapy (RRT) program, from the National Health System
perspective. METHODS: A deterministic Markov chain model,
allowing for incident patients, was designed to predict transitions
between four states (hemodialysis (HD), peritoneal dialysis (PD),
renal transplant (TX), and death (D)) for the period 2007/2016,
providing future incidence, prevalence, and survivability esti-
mates. Transition and mortality probabilities were calibrated
using data from the Spanish Nephrology Society (SEN) and the
Spanish National Statistics Institute (INE) for the period 1996/
2006. Information on direct and indirect costs was gathered from
several sources, including OBLIKUE database, regional ofﬁcial
bulletins, literature review, and expert judgment. Data on utilities
were obtained from a proprietary database (FIS 96/1327
Project). A sensitivity analysis on the main parameters of the
model was performed in order to ensure that results were con-
sistent. RESULTS: For the 2007/2016 period, average patients
per year (HD, PD, and TX) were, respectively: 29,981; 3,348;
26,301. Average costs per patient and year (in 2007 discounted
Euros) were: 39,026; 26,971; and 13,085. Average QALYs per
patient and year were: 0.51; 0.55; and 0.68. Therefore, average
cost-effectiveness was: 75,927; 49,478; and 19,253. TX was the
optimal treatment, regarding cost-effectiveness estimates. Conse-
quently, it was considered as the gold standard. Incremental
Cost-Effectiveness Ratios were: -103,233 (TX vs. HD) and
-156,636 (TX vs. PD). Net Health Proﬁts were: 1.03 (TX vs.
HD) and 0.60 (TX vs. PD). Consistency of these ﬁndings was
supported by the sensitivity analysis. CONCLUSIONS: As
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